Jacobs Levy Equity Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.9M	Buy	1,231,516 +134,327	+12%	+$2.15M	0.08%	221
2026 Q1	$16.3M	Sell	1,097,189 -42,060	-4%	-$615K	0.07%	235
2025 Q4	$18.2M	Sell	1,139,249 -80,202	-7%	-$1.14M	0.07%	222
2025 Q3	$13.5M	Buy	1,219,451 +471,338	+63%	+$5.15M	0.05%	251
2025 Q2	$6.34M	Buy	748,113 +430,457	+136%	+$3.45M	0.02%	385
2025 Q1	$2.55M	Buy	317,656 +304,420	+2,300%	+$2.47M	0.01%	600
2024 Q4	$119K	Buy	+13,236	New	+$108K	﹤0.01%	915
2022 Q4	–	Sell	-35,484	Closed	-$267K	–	943
2022 Q3	$267K	Buy	+35,484	New	+$307K	﹤0.01%	906

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's AUPH Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Aurinia Pharmaceuticals (AUPH) stake by 12% in Q2 2026, buying an estimated $2.15M and bringing the position to 1,231,516 shares worth $20.9M. The position accounts for 0.08% of the portfolio, ranked #221.

Jacobs Levy Equity Management first reported a position in AUPH in Q3 2022 and has held it in 8 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Jacobs Levy Equity Management held 1,231,516 shares of Aurinia Pharmaceuticals worth $20.9M as of Q2 2026.
Jacobs Levy Equity Management bought 134,327 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.15M.
Aurinia Pharmaceuticals made up 0.08% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #221 holding.
Jacobs Levy Equity Management first reported a position in Aurinia Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.